Financial & Policy Research Insights

A potential shift in UK drug pricing policy may open new revenue opportunities for pharma manufacturers amid trade negotiations with the U.S.

Explore how legislative shifts, funding cuts, and court rulings are reshaping ACA coverage, premiums, and insurer margins—plus what’s next for HSAs and ICHRAs in 2025 and beyond.

Six months into the Trump 2.0 administration, policy is a key driving force of investor outcomes.

Why New State Legislation Could Upend Business Models for CTRE, MPW, OHI, SBRA, and WELL.

In the first 100 days of the Trump administration, healthcare has shifted...

Get actionable insights into trade disputes, healthcare reform, defense funding, tech regulation, and energy market shifts with Washington Analysis’ comprehensive Q2 2025 outlook.

Get exclusive insights into the lawsuits challenging IEEPA tariffs and what’s next for U.S. trade policy and markets.

This exclusive Washington Analysis call explored the Trump administration’s food policy priorities, featuring an experienced regulatory attorney.

This research explores how potential PBM reform, IRA implementation, and pricing policy shifts may provide moderate tailwinds for retail pharmacy chains like CVS, WBA, and RiteAid in 2025.

Washington Analysis Healthcare Team hosted a conference call with a leading UK-based strategic advisor to understand better the potential...